Viridian Therapeutics, Inc./DE
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-14.8M | $-15.0M | $250.0K | $198.0K |
| FY2017 | $-28.2M | $-28.4M | $246.0K | $2.4M |
| FY2018 | $-26.8M | $-27.3M | $445.0K | $3.7M |
| FY2019 | $-36.1M | $-36.1M | $84.0K | $4.0M |
| FY2020 | $-29.8M | $-29.8M | $42.0K | $3.6M |
| FY2021 | $-54.6M | $-54.9M | $338.0K | $14.5M |
| FY2022 | $-93.8M | $-94.6M | $797.0K | $19.8M |
| FY2023 | $-184.2M | $-185.1M | $898.0K | $67.2M |
| FY2024 | $-232.3M | $-232.8M | $511.0K | $42.2M |
| FY2025 | $-276.4M | $-276.9M | $495.0K | $44.3M |